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Current vaccines against Streptococcus pneumoniae, a bacterial species that afflicts 
people by causing a wide spectrum of diseases, do not protect against all pneumococcal 
serotypes. Thus, alternative vaccines to fight pneumococcal infections that target common 
proteins are under investigation. One promising strategy is to take advantage of immune 
cross-reactivity between commensal and pathogenic microbes for cross-protection. In this 
study, we examined the antibody-mediated cross-reactivity between S. pneumoniae and 
Streptococcus mitis, a commensal species closely related to S. pneumoniae. Western blot 
analysis showed that rabbit antisera raised against S. mitis reacted with multiple proteins 
of virulent S. pneumoniae strains (6B, TIGR4, and D39). Rabbit anti-S. pneumoniae IgG 
antibodies also showed binding to S. mitis antigens. Incubation of rabbit antisera raised 
against S. mitis with heterologous or homologous bacterial lysates resulted in marked 
inhibition of the developments of bands in the Western blots. Furthermore, plasma IgG 
antibodies from adult human volunteers intranasally inoculated with S. pneumoniae 6B 
revealed enhanced S. mitis-specific IgG titers compared with the pre-inoculation samples. 
Using an on-chip protein microarray representing a number of selected membrane and 
extracellular S. pneumoniae proteins, we identified choline-binding protein D (CbpD), cell 
division protein (FtsH), and manganese ABC transporter or manganese-binding adhesion 
lipoprotein (PsaA) as common targets of the rabbit IgG antibodies raised against S. mitis or 
S. pneumoniae. Cumulatively, these findings provide evidence on the antibody-mediated 
cross-reactivity of proteins from S. mitis and S. pneumoniae, which may have implications 
for development of effective and wide-range pneumococcal vaccines.
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inTrODUcTiOn
Streptococcus pneumoniae is a Gram-positive bacterial species that resides in the nasopharynx and 
oral cavity of humans and causes a wide spectrum of diseases, including pneumonia, meningitis, and 
septicemia (1). On the other hand, Streptococcus mitis, a commensal that exhibits genetic and ecological 
similarity with S. pneumoniae, is one of the most abundant members of the oral microbiota and rarely 
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causes disease (2). Clinic-epidemiological studies indicate that 
S. pneumoniae is the fourth most frequent cause of lethal infec-
tions and inflicts death on more than a million children under the 
age of 5 years worldwide (3, 4). In addition, immunocompromised 
and elderly individuals are highly susceptible to S. pneumoniae 
infections (3, 5). Although current pneumococcal vaccines, both 
conjugated (PCV7, 10, and 13) and unconjugated (PPSV23), have 
reduced the occurrence of diseases, they are unable to confer 
protective immunity against all S. pneumoniae serotypes (more 
than  90) (6, 7). Recent reports showing replacement by non- 
vaccine serotypes pose grave  concern (7). Therefore, novel prophy-
lactic strategies are needed to develop better vaccines that could 
provide long-term protection against all pneumococcal serotypes.
Understanding host immunity to pneumococcal infections 
is crucial for identifying immune targets for vaccine develop-
ment. Several studies involving mouse models of S. pneumoniae 
indicate that both arms of the adaptive immunity (antibody and 
T  cell) play an important role in mounting protective immu-
nity to infection (8–14). In a mouse model of nasopharyngeal 
colonization by S. pneumoniae, it was shown that mice deficient 
in CD4+ T  cells or IL-17 had a reduced ability to clear strep-
tococcal carriage compared with control mice (12). By contrast, 
protective immunity to septicemia after previous colonization is 
conferred by antibody-mediated (IgG and IgA) immunity (14). 
This suggests that the type of protective immune response against 
pneumococcal infections is largely influenced by the site of infec-
tion. Using a murine model of nasopharyngeal colonization by 
S. pneumoniae EF3030 followed by lung infection, Wilson et al. 
recently showed that colonization-induced protection in mice 
deficient in B cells, CD4+ T cells or IL-17 is impaired, suggesting 
that naturally acquired immunity to S. pneumoniae lung infec-
tion requires both humoral and cellular immunity (13). This has 
also been confirmed in controlled human infection studies with 
pneumococcus. Following experimental colonization, volunteers 
protected against subsequent re-colonization with the same strain 
presented increased pneumococci-specific antibodies as well as 
CD4+ T cells (8). On the other hand, how the host responds to 
S. mitis is poorly understood. Salivary IgA antibodies reactive to 
S. mitis antigens have been reported in human infants (15–17). 
Our recent study has shown that human CD4+ T  cells, which 
express IL-17 (Th17  cells) and are reactive with S. mitis, also 
respond to pneumococcal proteins when cocultured with 
antigen-presenting cells pulsed with S. pneumoniae (18).
Currently available pneumococcal vaccines provide immunity 
that is mediated by serotype-specific antibody responses, which has 
limitations as this protection is restricted to only 7–23 serotypes. 
In addition, capsular polysaccharide vaccines are more  protective 
against invasive pneumococcal diseases than non-invasive dis-
eases, such as otitis media (5, 6). A novel approach to deal with 
these limitations and provide broader serotype  coverage could 
be to exploit the immune cross-reactivity between commensal 
and pathogenic microbes. The antibodies generated against 
commensal microbes have been reported to cross-react with 
pathogens (18–20). Although a few studies have examined the 
serological cross-reactivity of polysaccharide antigens between 
S. mitis and S. pneumoniae, it remains unclear whether antibod-
ies specific to S. mitis cross-react with pneumococcal proteins 
(21–23). In this study, we hypothesized that antibodies elicited 
against S. mitis and S. pneumoniae show cross-reactivity to 
S. pneumoniae and S. mitis proteins, respectively. To test this 
hypothesis, we examined the ability of antibodies raised against 
S. mitis or S. pneumoniae to cross-react with S. pneumoniae 
and S. mitis and attempted to identify pneumococcal protein 
antigens that react with the antibodies. Our findings shed light 
on the antibody-mediated cross-reactivity between S. mitis and 
S. pneumoniae. This may have implications for designing effective 
prophylactic strategies against pneumococcal infections. S. mitis-
based vaccines can induce the production of antibodies reactive 
to S. pneumoniae proteins, resulting in serotype-independent 
protection against pneumococci.
MaTerials anD MeThODs
Bacterial strains, culture, and lysis
Streptococcus mitis strain used was CCUG31611 (type strain, 
equivalent to NCTC12261), whereas S. pneumoniae strains 
included TIGR4, D39, and BHN418 (6B). The BHN418 6B 
strain was used in Experimental Human Pneumococcal Carriage 
(EHPC) studies (8). All strains were stored at −80°C in trypticase 
soy broth (Becton Dickinson, Franklin Lakes, NJ, USA), and 15% 
glycerol. Before use, stock cultures were diluted 1:10, followed by 
growth at 37°C to an optical density (OD) of 0.5 at 600 nm in 
a 5% CO2 incubator. The bacterial cells were harvested by cen-
trifugation at 5,000 g for 10 min at 4°C and washed in endotoxin 
free Dulbecco’s-PBS (Sigma-Aldrich, St. Louis, MO, USA) for 
further processing. To lyse the bacterial cells, a Precellys Lysing 
Kit and Homogenizer (Precellys 24, Bertin Instruments) was 
used as per the manufacturer’s instruction. In brief, the bacterial 
cells dissolved in cold PBS were poured into the Precellys Lysing 
tube prefilled with high quality glass beads (0.5 mm) and homog-
enized for disruption of bacterial cells (Precellys 24 homogenizer; 
program 2). After homogenization, the bacterial cell lysate was 
centrifuged at 1,000 g for 5 min at 4°C and the supernatant was 
collected and stored at −80°C for further use. The total protein 
in the cell lysate was quantified using BCA Protein Assay Kit 
(ThermoFischer Scientific).
raising antisera
Streptococcus mitis antisera were obtained from specific patho-
gen free New Zealand White rabbits (ProteoGenix, France). 
Rabbits were subcutaneously immunized with 10 × 106 colony-
forming units (CFUs) of ultraviolet-killed S. mitis type strain 
(CCUG31611) twice at an interval of 2 weeks, and the antisera 
were collected at day 28 after the first immunization. We also pur-
chased rabbit antisera raised against whole cell of S. pneumoniae 
serotypes; (1) Type serum 2 against 1, 2, 4, 5, 11, 18, 20, 22, and 
33 serotypes (SSI Diagnostica, Denmark) and (2) pooled antisera 
against S. pneumoniae 3, 4, 6, 9, 14, 18, 19, and 23 surface antigens 
(Meridian Life Sciences, TN, USA), for specific experiments. 
Pre- and post-inoculation plasma samples from human volun-
teers intranasally inoculated with S. pneumoniae were received 
from the EHPC collaboration at the Liverpool School of Tropical 
Medicine, Liverpool, UK (24). In brief, 13 healthy individuals of 
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18–50 years of age were inoculated with 8 × 104 CFU per 100 µl of 
S. pneumoniae 6B (BHN418) per naris, which eventually devel-
oped pneumococcal carriage, as previously described (24). Plasma 
samples were collected at baseline and at day 21 post-inoculation 
and stored at −80°C (24). The individuals naturally colonized 
with pneumococcus at baseline or in regular contact with at-risk 
individuals were excluded. Of note, both informed and written 
consent was obtained from the participants. Ethical approvals 
were obtained from the National Health Service Research Ethics 
Committee (12/NW/0873).
Western Blot and immunoinhibition assay
SDS-PAGE-separated proteins were transferred from gradient gels 
(4–20%) to nitrocellulose membranes using a constant voltage of 
100 V for 2 h using the BioRad Midi-PROTEAN Western blotting 
module according to the manufacturer’s instructions (BioRad, 
CA, USA). The membranes were blocked with blocking solution 
[Tris-buffered saline (TBS) (pH 7.4) containing 0.1% Tween 
20 (Sigma-Aldrich) and 5% BSA] for 1 h at room temperature, 
washed three times with TBS-Tween, and incubated overnight 
with antisera at 4°C. Following the incubation, the membranes 
were washed and finally incubated with AP-conjugated goat anti-
rabbit or antihuman IgG secondary antibodies and later developed 
with the substrate (4-chloro-1-naphthol). Of note, the exposure 
time was similar for the membranes treated with pre- and post-
inoculation serum/plasma samples. For immunoinhibition assays, 
lysates from S. mitis CCUG31611 and S. pneumoniae 6B were 
immobilized on CNBr-activated Sepharose 4B beads  according to 
the instructions of the manufacturer (GE Healthcare, Germany). 
After blocking with 0.2 M glycine (pH 8), the beads were washed 
and used for absorption of rabbit anti-S. mitis antibodies. 
Following absorption, the unabsorbed serum antibodies were 
used to perform immunoblotting.
elisa
Bacterial whole-cell ELISAs were performed to measure the levels 
of antibodies. Briefly, each well of a 96-well plate (Maxisorb, 
Nunc, Thermo Scientific) was coated overnight with 100  µl of 
bacterial suspension (OD600 0.5), which was washed and then 
fixed with 10% formalin. The plate was washed four times (200 µl 
PBS + 0.05% Tween) before addition of 100 µl blocking buffer 
(PBS + 0.05% Tween + 1% BSA) and incubation for 1 h at 37°C. 
Serially diluted plasma samples were added to wells in duplicate, 
incubated for 2  h at room temperature before addition of the 
anti-IgG/HRP secondary antibody diluted 1:10,000, followed by 
incubation for 2 h at room temperature, washing and addition 
of 100 µl of TMB substrate (ThermoFisher Scientific, Rockford, 
IL, USA) to each well. The plates were then incubated in the 
dark at room temperature for 15 min, after which stop solution 
(ThermoFisher Scientific, Rockford, IL, USA) was added to each 
well to terminate the reaction, and absorbance was measured by 
reading the plates at 450  nm using a cell imaging Multi-Mode 
reader (BioTek™ Cytation™ 3; ThermoFischer Scientific). For 
evaluation, titration curves were established for each measure-
ment and cutoffs applied to convert serum activities into titers. 
For estimation of titers, cutoffs were placed at OD450 = 0.4 for the 
rabbit hyperimmune sera and OD450 =  0.2 for the human sera 
because those values were within the linear parts of the titration 
curves. As an example, an ELISA titration curve has been pro-
vided as Figure S2 in Supplementary Material.
Production and Overexpression  
of recombinant Proteins
E. coli clones for expression of the S. pneumoniae TIGR4 
recom-binant proteins were generated at John Craig Venter 
Institute, USA, whereas expression clones for the S. mitis type 
strain recombinant proteins were constructed at the Department 
of Oral Biology, University of Oslo, Norway. Gateway cloning 
strategy was used to generate expression clones for the produc-
tion of recombinant proteins. Briefly, S. mitis target genes were 
amplified using the oligonucleotide primers listed in Table S1 
in Supplementary Material. S. pneumoniae and S. mitis genes 
cloned in entry clone pDONR221 were transferred into the 
destination vector T02, which encodes a hexa-histidine tag 
at the amino terminal as described previously (25). The cloned 
inserts were sequence validated before transformation of T02 
destination vector into E. coli expression strain BLR (DE3). 
For overexpression of recombinant proteins, frozen stock of E. 
coli BLR (DE3)-containing expression clones were inoculated 
in 1 ml 2× YT medium in deep 96-well blocks with ampicillin 
(100 µg/ml) and tetracycline (12.5 µg/ml). The bacterial cultures 
were incubated at 37°C with shaking at 800 rpm. Upon reaching 
an OD600 of 0.7–0.9, protein expression was induced by addition 
of isopropyl-β-d-1-thiogalactopyranoside (IPTG) at a final 
concentration of 1 mM, and incubation proceeded overnight at 
25°C at 900 rpm. The overnight cultures were then collected by 
centrifugation at 3,500 rpm at 4°C for 20 min. The pellets were 
resuspended in 90 µl low salt lysis buffer (50 mM Tris, 100 mM 
NaCl, 10  mM imidazole, pH 7.3), 1  mM DTT, 1  µl lysonase 
(Novagen), and 200  µM aminoethyl benzenesulfonyl fluoride 
hydrochloride (AEBSF) protease inhibitor and incubated for 
20 min at room temperature. To complete the lysis process, 10 µl 
of pop culture (Novagen) was added and incubated for 30 min at 
room temperature. The bacterial lysate was run on the Nu-PAGE 
gel (Invitrogen Nu-PAGE 12% Bis–Tris gel) to validate expression 
and size of proteins.
On-chip Purification of Protein Microarray 
and Testing With antiserum
High-density Cu++ chelated slides (MicroSurfaces, Inc., 
Englewood, NJ, USA) were used for on-chip purification of 
hexa-His tagged recombinant proteins as previously described 
(26). Slides were incubated at room temperature in a humidity 
chamber for 30 min before printing. Cell lysates were diluted 1:20 
in printing buffer PBST (10 mM phosphate buffer, 2.7 mM KCl, 
140 mM NaCl, 0.05% Tween 20, pH 7.4) and printed manually on 
chips with Microcaster array tool (Whatman). Slides were dried 
in 70% humidity chamber at room temperature. The printed 
slides were assembled in the fast frame incubation chamber 
(Whatman) and blocked with blocking buffer (RayBiotech) for 
30 min at room temperature. The antisera were cleaned up with 
FigUre 1 | Reactivity of rabbit antisera raised against Streptococcus mitis 
with Streptococcus pneumoniae strains (6B, TIGR4, and D39) by SDS-PAGE 
in gradient gels and immunoblotting. Each lane was loaded with 50 µg of 
protein from the indicated bacterial species. The pre- and post-inoculation 
sera were diluted 1:1,000. (a,B) Antisera from rabbit-1 and rabbit-2, which 
were immunized with S. mitis CCUG31611. The experiment was performed 
twice. Abbreviations: PRE, pre-inoculation sera; POST, post-inoculation sera.
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E. coli lysate and protease inhibitor cocktail by incubation and 
spinning down. Blocking buffer was removed, the cleaned and 
diluted 1:100–1:1,000 antisera in blocking buffer were added on 
the slides and incubated for 1  h. After incubation, the arrayed 
slides were washed with 1 ml PBST four times by incubating for 
2 min between each wash. Alexa-647 conjugated goat anti-rabbit 
antibody was also cleaned with E. coli cell lysate and applied on 
the slide and the secondary antibody on the array was incubated 
for 1 h. The arrays were washed with PBST four times for 2 min 
each wash. The array assembly was departed, and the array slide 
was put into a 30 ml washing tube and washed with PBST for 
15 min. Then, the array slides were rinsed with water and dried 
by centrifugation. To detect immobilized recombinant proteins, 
Alexa-555 conjugated anti-hexa-His tag antibody (ThermoFisher 
Scientific) was cleaned with E. coli lysate, diluted to 1:1,000 in 
blocking buffer, applied on the array slide and incubated for 
1 h. After incubating, the array slides were washed and dried as 
described earlier. Slides were scanned using Genepix 4000B and 
quantified using Genepix Pro 4.0.
Purification of Psaa Protein of S. mitis and 
S. pneumoniae
The PsaA protein of S. mitis and S. pneumoniae was purified using 
Dynabeads TALON which utilizes cobalt based immobilized metal 
affinity chromatography. E. coli BLR (DE3) expression clones 
 containing PsaA gene from S. mitis and S. pneumoniae were grown 
in 50 ml 2× YT medium supplemented with ampicillin (100 µg/ml) 
and tetracycline (12.5 µg/ml). Protein expression was induced by 
IPTG at OD600 0.6 followed by incubation at 25°C for 4 h at 200 rpm. 
Cells were harvested by centrifugation, and cell pellets were stored 
overnight at −80°C. For cell lysis, pellets were resuspended in B-PER 
complete bacterial protein extraction reagent (ThermoFisher 
Scientific). Supernatant was collected by centrifugation of cell 
lysates at 16,000 g for 20 min and subjected to His-tag protein puri-
fication using Dynabeads TALON (Dynal biotech) according to the 
manufacturer’s instructions. The purified proteins were analyzed 
by SDS-PAGE gel electrophoresis, and reactivity to S. mitis and S. 
pneumoniae rabbit antisera was assessed using Western blot.
statistical analysis
Wilcoxon Signed Rank tests were applied using the SigmaPlot 
v13, Systat Software Inc., London, UK. p Values <  0.05 were 
considered to be significant.
resUlTs
igg antibodies specific to S. mitis  
cross-react With Different  
S. pneumoniae serotypes
To assess the reactivity of antibodies raised against S. mitis with 
pneumococcal antigens, we used antisera from rabbits that 
received S. mitis type strain (rabbit 1 and rabbit-2), and performed 
SDS-PAGE and immunoblotting. We found an enhanced binding 
of the IgG antibodies from S. mitis antisera (rabbit-1 and rabbit-2), 
compared with the pre-immunized sera, to the proteins from S. 
pneumoniae serotypes (6B, TIGR4, and D39), as shown by multiple 
stronger bands (Figures 1A,B). Most of the strongest bands were 
present at the level of molecular weight 50 kDa for all the S. pneu-
moniae serotypes (Figures 1A,B). Interestingly, a clear and thick 
band of molecular weight between 50–75 kDa was found in the lane 
receiving 6B pneumococcal protein, but absent from all other lanes 
including the one that had S. mitis proteins (Figure 1A). Of note, 
we did not find any appreciable bands while examining the bind-
ing of IgA antibodies to pneumococcal proteins (data not shown). 
After having immunoblotting data on the cross-reactivity of 
S. mitis antisera, we sought to examine the titer of anti-S. mitis  rabbit 
IgG antibodies reactive to pneumococcal proteins. We found an 
increased titer of the IgG antibodies reactive to S. pneumoniae and 
S. mitis compared with the antibodies from unimmunized rabbits 
(Figure 2; nota bene as titers were used, lower numbers indicate 
higher antibody concentration, please see legend). To further 
confirm the cross-reactivity between S. mitis and S. pneumoniae, 
we performed an immunoinhibition assay by incubating rabbit 
anti-S. mitis sera with immobilized S. pneumoniae 6B or S. mitis 
lysates. Upon immunoblotting, the S. mitis antisera incubated 
with S. pneumoniae 6B or S. mitis exhibited significant inhibi-
tion of bands for S. mitis and S. pneumoniae compared with the 
antisera without antibody absorption (Figure 3). Similar findings 
were observed when we looked for the bacteria-specific IgG titer 
in the antisera with different incubations (Figure 3). Overall, these 
findings show that IgG antibodies specific to S. mitis cross-react 
with S. pneumoniae.
FigUre 2 | Levels of Streptococcus pneumoniae-reactive IgG antibodies from pre- or post Streptococcus mitis-immunized rabbits. The titer of IgG antibodies 
was determined using whole-cell ELISA. Antisera were used from rabbit-1 and rabbit-2, immunized with S. mitis CCUG31611. The serum samples were serially 
diluted, and the OD values converted to titers, with a cutoff of OD value of 0.40 (see Materials and Methods; low numbers indicate high antibody concentration,  
e.g., 0.002 = 1/500 and 0.004 = 1/250). The bars show averages of two replicates. Abbreviations: PRE, pre-inoculation sera; POST, post-inoculation sera.
FigUre 3 | Immunoinhibition for IgG cross-reactivity between Streptococcus 
mitis and Streptococcus pneumoniae. For SDS-PAGE, wells were loaded 
with 50 µg of protein from S. mitis CCUG31611 and S. pneumoniae strains. 
After blotting, untreated rabbit S. mitis antiserum or the same antiserum 
pre-incubated with immobilized S. mitis or S. pneumoniae 6B lysates were 
used to detect immunoreactivity. Levels of S. mitis or S. pneumoniae-reactive 
IgG antibodies in the same antiserum preparations. The levels of IgG 
antibodies were determined using whole-cell ELISA. The OD values were 
converted to titers, with a cutoff of OD value of 0.40 (see legend to Figure 2). 
The bars show averages of two replicates.
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against S. pneumoniae to examine the reactivity of the antisera IgG 
antibodies with S. mitis proteins. Our findings demonstrated an 
enhanced binding pattern of anti-S.  pneumoniae IgG  antibodies 
to S. mitis and S. pneumoniae strains, particularly 6B and TIGR4, 
when compared with the control antibodies from unimmunized 
rabbits (Figure  4A). However, the post-inoculation  binding 
 pattern for S. mitis had some differences compared with 
S.  pneumoniae 6B and TIGR4 (Figure 4A). Similarly, the levels 
of anti-S. pneumoniae IgG titer reactive to S. mitis increased 
compared with the antibody levels of pre-immunized serum 
(Figure 4B). To validate these rabbit findings to humans, we used 
plasma samples from 13 healthy adults intranasally inoculated 
with S. pneumoniae 6B, which eventually acquired pneumococcal 
carriage (24). Our whole-cell ELISA experiments revealed that 
plasma IgG antibodies from humans inoculated with S. pneumo-
niae show increased reactivity to S. mitis and S. pneumoniae 6B 
compared with the pre-inoculation samples (Figure  5). Taken 
together, these data indicate that cross-reactivity is conferred by 
pneumococcal antibodies against S. mitis antigens.
identification of Pneumococcal Proteins 
That cross-react With S. mitis antisera
Pneumococcal surface proteins have been shown to induce host 
responses to S. pneumoniae, underscoring the potential of these 
proteins as potent vaccine candidates (6, 7). Our Western blot 
data show that some of the most prominent bands, which devel-
oped due to reaction between S. pneumoniae/S. mitis proteins 
and anti-S. mitis IgG antibodies had a molecular weight around 
50 kDa (Figure 1). To identify some of the bacterial proteins that 
cross-react with anti-S. mitis IgG antibodies, we selected a panel 
enhanced reactivity of antisera raised 
against S. pneumoniae to S. mitis
To understand whether antibodies specific to S. pneumoniae can 
in turn cross-react with S. mitis, we used rabbit antisera raised 
FigUre 5 | Levels of Streptococcus mitis- and Streptococcus pneumoniae-reactive IgG antibodies isolated from S. pneumoniae 6B-inoculated adults. Pre- and 
post-inoculation plasma samples were collected from 13 individuals inoculated with S. pneumoniae 6B. Serially diluted plasma samples were added to wells in 
duplicate. The OD values were converted to titers, with a cutoff value of 0.20 (see legend to Figure 2). The levels of IgG antibody titers against S. mitis and  
S. pneumoniae strains are shown. OD values are shown for each subject at pre- and post-challenge time points. (a) Pre- and post-challenge IgG levels to S. mitis  
and S. pneumoniae 6B. (B) Pre- and post-challenge IgG levels to S. mitis and S. pneumoniae 6B linked for each subject. Wilcoxon Signed Rank Test, *p < 0.05; 
***p < 0.001. Abbreviations: PRE, pre-inoculation sera; POST, post-inoculation sera.
FigUre 4 | Reactivity of rabbit antiserum raised against Streptococcus pneumoniae with Streptococcus mitis. (a) Reactivity of a rabbit antiserum raised against a 
pool of S. pneumoniae serotypes (1, 2, 4, 5, 11, 18, 20, 22, and 33), with S. mitis and S. pneumoniae strains (6B, TIGR4, and D39) using SDS-PAGE and 
immunoblotting. Each lane was loaded with 50 µg of protein from each bacterial species. The pre- and post-inoculation sera were diluted 1:1,000. (B) Pre- and 
post-immunization levels of S. mitis-reactive IgG antibodies from a S. pneumoniae-immunized rabbit. The titer of IgG antibodies was determined by converting the 
OD values to titers, with a cutoff of OD value of 0.40 (see legend to Figure 2). The bars show averages of two replicates. Abbreviations: PRE, pre-inoculation sera; 
POST, post-inoculation sera.
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TaBle 1 | List of Streptococcus pneumoniae proteins selected for on-chip protein microarray experiments.
locus iD 
S. pneumoniae Tigr4 
Protein subcellular 
location
Molecular weight (Da) Ortholog in  Streptococcus 
mitis ncTc12261
% identity
SP0013 Cell division protein FtsH Membrane 71,326 NAa 93
SP0091 ABC transporter; permease protein Membrane 34,545 SM12261_0720 93
SP0092 ABC transporter substrate-binding protein Extracellular 54,485 SM12261_0719 92
SP0102 Glycosyl transferase Membrane 40,703 No significant similarity –
SP0107 LysM domain protein Extracellular 20,921 SM12261_0703 96
SP0117 Surface protein A Membrane 82,764 No significant similarity –
SP0385 Hypothetical protein Membrane 27,192 SM12261_1022 95
SP0523 ABC transporter, permease protein, putative Membrane 40,505 SM12261_0538 94
SP0704 Hypothetical protein Membrane 28,261 No significant similarity –
SP0749 Branched-chain amino acid ABC transporter;  
amino acid-binding protein (livJ)
Extracellular 40,414 SM12261_0255 94
SP0751 Branched-chain amino acid ABC transporter;  
permease protein (livM)
Membrane 33,564 SM12261_0253 96
SP0954 Competence protein CelA Membrane 23,181 SM12261_1388 92
SP1002 Adhesion lipoprotein (lmb) Extracellular 33,951 SM12261_0792 93
SP1067 Cell division protein FtsW; putative Membrane 45,449 No significant similarity –
SP1069 Conserved hypothetical protein Extracellular 36,428 SM12261_1418 90
SP1264 Conserved domain protein Membrane 38,825 No significant similarity –
SP1400 Phosphate ABC transporter, phosphate- 
binding protein, putative
Extracellular 31,201 SM12261_0153 78
SP1601 Conserved hypothetical protein Membrane 24,619 SM12261_0284 92
SP1604 Hypothetical protein Membrane 16,812 SM12261_0287 79
SP1628 Hypothetical protein Membrane 8,493 NA 97
SP1650 Manganese ABC transporter; manganese- 
binding adhesion lipoprotein (PsaA)
Extracellular 34,593 SM12261_0346 95
SP1684 PTS system; IIBC components Membrane 54,471 SM12261_0375 98
SP1839 ABC transporter ATP-binding protein/ 
permease
Membrane 65,551 NA 92
SP1952 Hypothetical protein Membrane 36,169 No significant similarity –
SP1964 DNA-entry nuclease (endA) Membrane 29,890 SM12261_0490 93
SP2013 Conserved hypothetical protein Membrane 35,985 No significant similarity –
SP2051 Competence protein CglC (cglC) Membrane 12,177 SM12261_0632 91
SP2108 Maltose/maltodextrin ABC transporter  
maltose/maltodextrin-binding protein
Extracellular 45,337 SM12261_0678 96
SP2201 Choline-binding protein D Extracellular 50,349 SM12261_0760 89
SP2239 Serine protease Membrane 41,842 SM12261_0790 94
aNA, not annotated in the NCBI database, but present in the genome sequences.
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of 30 predicted extracellular and membrane proteins that have 
around 50 kDa molecular weight (Table 1) and analyzed them 
using on-chip high quality protein microarray. An array map has 
been included that shows the position of S. pneumoniae TIGR4 
proteins printed and immobilized on high-density Cu++ chelated 
slides (Table S2 in Supplementary Material). The immobilized 
proteins on microarray chips were visualized using Alexa-555 
conjugated anti-His-tag antibody. Data analysis identified three 
different pneumococcal proteins with signal ratio (Fsample/FE. coli) 
>  1.5—choline-binding protein D (CbpD; SP2201), cell 
division protein (FtsH; SP0013), and manganese ABC trans-
porter or manganese-binding adhesion lipoprotein (PsaA; 
SP1650)—upon treatment with antisera (IgG) against S. mitis  
(Figure  6; Table  2). Maltose/maltodextrin-binding protein 
(SP2108) was identified using antisera against S. pneumoniae, 
but not with antisera against S. mitis (Figure 6A). S. pneumoniae 
PsaA, in particular, is a protein with immunogenic activity that 
has been investigated in several studies as a potential vaccine 
against pneumococcal infections (27–29). Thus, we cloned and 
expressed the S. mitis PsaA in E. coli to check it for cross- reactivity 
with antibodies raised against S. mitis and S. pneumoniae. Our 
Western blot analysis revealed a stronger binding of rabbit 
S. mitis and S. pneumoniae antisera to PsaA compared with the 
pre-inoculation serum (Figure  6B). The original immunoblot 
has been provided (Figure S1 in Supplementary Material). Thus, 
we identified three common proteins, CbpD, FtsH, and PsaA, 
derived from S. pneumoniae reactive to antisera raised against 
S. mitis or S. pneumoniae. We also found that purified PsaA from 
S. mitis reacted with the antisera against S. mitis, suggesting 
similar cross-reactive responses for protein antigens from S. mitis 
and S. pneumoniae.
DiscUssiOn
The aim of this study was to examine the antibody-mediated 
cross-reactivity between S. pneumoniae and the commensal 
S. mitis and to identify common cross-reactive protein antigens 
using multiple experimental approaches. The major findings of 
the study include the following: (1) rabbit IgG antibodies raised 
with S. mitis cross-react with S. pneumoniae; (2) rabbit anti- 
S. pneumoniae IgG antibodies show cross-reactivity with S. mitis; 
(3) IgG antibodies from humans inoculated with S. pneumoniae 
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demonstrate increased reactivity to S. mitis; and (4) antisera 
raised against S. mitis recognize specific S. pneumoniae and 
S. mitis surface proteins.
Our findings demonstrated that antisera raised with S. mitis 
in rabbits cross-react with S. pneumoniae serotypes (6B, TIGR4 
of different serotypes, and D39). Cross-reactions have been 
documented among microbial proteins with similar evolution-
ary development and struc-ture, e.g., antibody cross-reactivity 
between proteins from the commensal Neisseria lactamica and 
the pathogenic Neisseria meningitidis (20, 30). Previous studies 
suggest that S. mitis and S. pneumoniae share a close genetic 
relatedness with around 80% genome similarity, and that several 
pneumococcal proteins are ubiquitously present in S. mitis 
(31, 32). Therefore, it is understandable why many S. mitis and 
S. pneumoniae proteins are reactive to antisera against S. mitis 
as shown in this study. These findings are in line with human 
studies where salivary antibodies (IgA) were found to react 
with S. mitis (15–17). Since we did not find significant differ-
ences between the post-inoculation antibody levels reacting to 
S. mitis and S. pneumoniae strains, it may be inferred that the 
pneumococcal cross-reactive antigens and their ability to bind 
with S. mitis antisera were similar. Another important finding in 
our study is that IgG antibodies from humans inoculated with 
S. pneumoniae show increased reactivity to S. mitis as well as 
S. pneumoniae 6B, as demonstrated by whole-cell ELISA data. 
This is in accordance with previous studies showing that S. pneu-
moniae carriage promotes an increase in IgG responses specific 
to protein and capsular antigens of S. pneumoniae 6B (8). Overall, 
these findings support the concept that natural immunity against 
pneumococcal diseases could be partially due to nasopharyngeal 
and oral colonization by S. mitis, and this may have consequences 
in the design of better prophylactic strategies for containing 
infections for all pneumococcal serotypes.
In the on-chip protein microarray analysis, we evaluated 30 
different proteins with a molecular weight of around 50 kDa, as 
major pneumococcal bands in the immunoblotting experiments 
were found within this range. We identified three pneumococcal 
proteins that showed reactivity with antibodies (IgG) against both 
S. mitis and S. pneumoniae. These proteins included CbpD, PsaA, 
and FtsH, which are present in the two species and show more 
FigUre 6 | Identification of pneumococcal proteins that cross-react with rabbit Streptococcus mitis antisera. (a) Immunogenic screening of on-chip purified 
Streptococcus pneumoniae TIGR4 protein microarray. Lysates of 30 recombinant proteins overexpressed in E. coli were printed on the chelated Cu++/PEG surface 
slides in triplicates. The slides were probed with S. mitis and S. pneumoniae antiserum to identify immunoreactive pneumococcal antigens. Pre- and post-immune 
serum from rabbits challenged with S. mitis type strain, and post-immune serum from rabbits challenged with S. pneumoniae were used on the slides. Values were 
obtained by ratio of fluorescence intensity of spot to fluorescence intensity of E. coli cell lysate. E. coli, His-tag MBP; ~50% similarity to SP2108. Abbreviations: 
PRE-SM, pre-inoculation S. mitis serum; POST-SM, post-inoculation S. mitis serum; POST-SP, post-inoculation S. pneumoniae serum; CbpD, choline-binding 
protein D; FtsH, cell division protein; PsaA, manganese ABC transporter adhesion lipoprotein; MBP, maltose-binding protein. (B) Reactivity of rabbit anti-S. mitis IgG 
antisera with S. pneumoniae TIGR4 and S. mitis PsaA by SDS-PAGE in gradient gels and immunoblotting. Each lane was loaded with 50 µg of protein from the 
indicated bacterial species. The pre- and post-inoculation sera were diluted 1:1,000. Abbreviations: M, S. mitis CCUG31611; P, S. pneumoniae TIGR4.
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TaBle 2 | Quantification of fluorescence signal ratio of on-chip purified 
Streptococcus pneumoniae proteins obtained by ratio of fluorescence intensity  
of spot to fluorescence intensity of E. coli lysate.
S. pneumoniae Streptococcus mitis
average sD average sD
Buffer 0.9 0.1 1.0 0.3
E. coli_lysate 1.0 0.2 1.0 0.4
SP0013a 2.1 0.4 1.9 0.5
SP0091 1.0 0.1 1.0 0.3
SP0092 1.4 0.2 1.1 0.3
SP0102 1.2 0.2 1.1 0.3
SP0107 0.9 0.1 1.1 0.3
SP0117 2.0 0.4 1.4 0.4
SP0385 1.2 0.2 1.4 0.4
SP0523 1.2 0.2 1.0 0.3
SP0704 1.1 0.3 0.9 0.3
SP0749 1.1 0.1 1.0 0.3
SP0751 1.1 0.1 1.1 0.4
SP0954 1.2 0.2 1.0 0.3
SP1002 1.3 0.2 1.2 0.3
SP1067 1.0 0.2 1.1 0.4
SP1069 1.0 0.1 1.2 0.4
SP1264 2.1 0.4 1.2 0.4
SP1400 1.1 0.1 1.0 0.4
SP1601 1.2 0.2 1.1 0.6
SP1604 1.5 0.2 1.0 0.4
SP1628 1.3 0.2 1.2 0.3
SP1650a 41.3 6.4 2.4 0.7
SP1684 1.3 0.2 1.1 0.5
SP1839 1.1 0.1 1.1 0.3
SP1952 1.4 0.3 1.3 0.5
SP1964 1.3 0.4 1.2 0.6
SP2013 1.3 0.1 1.3 0.4
SP2108 2.7 0.9 1.2 0.3
SP2201a 2.7 0.6 1.6 0.5
SP2239 1.1 0.2 1.0 0.4
aSignal intensity ratio > 1.5 for both S. pneumoniae and S. mitis.
Average values were calculated from three replicates.
than 90% similarity. CbpD and PsaA are extracellular proteins 
that belong to the family of choline-binding proteins (CBP) 
and are shown to contribute to nasopharyngeal colonization by 
S. pneumoniae and competence-induced cell lysis (27, 33). So far, 
several studies on pneumococcal infections conducted in animal 
models have demonstrated an antibody-mediated protection 
induced by CBP members, such as PspC and PsaA (27–29). 
However, the immunogenic potential of CbpD is still unclear. 
Given the fact that CbpD facilitates nasopharyngeal colonization 
by S. pneumoniae and that it possesses ~90% similarity with its 
ortholog (SM12261_0760) in S. mitis, CbpD holds promise as 
an immunogenic candidate against S. pneumoniae serotypes, 
 warranting further exploration to assess its efficacy to mount pro-
tective immunity that is independent of pneumococcal serotypes. 
A combined formulation of a vaccine containing PsaA and PspA 
has been shown to prevent bacterial colonization and otitis media 
in animal models (34, 35). It would be interesting to investigate 
the immunogenic potential of a combination of PsaA, FtsH, and 
CbpD, which may confer an additive protective effect as well as 
limit the occurrence of allelic variation within these individual 
proteins.
In conclusion, our findings demonstrate that antibodies raised 
against S. mitis and S. pneumoniae cross-react with S. pneumoniae 
and S. mitis proteins, respectively. These findings are in accord-
ance with our hypothesis that antibodies elicited against S. mitis 
and S. pneumoniae show cross-reactivity to S. pneumoniae and 
S. mitis proteins, respectively. It is important to note that  reactivity 
of S. mitis-specific antibodies with pneumococcal proteins 
provides a platform upon which the development a serotype-
independent protein-based pneumococcal vaccine with extended 
coverage can be carried out. Future studies need to assess whether 
antibody responses due to nasopharyngeal colonization by S. mitis 
generate cross-protection against S. pneumoniae infections. In 
addition, it is worth testing the effect of cross-reactive antigens 
on rendering protection against diverse S. pneumoniae serotypes.
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